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The myofilament protein, cardiac troponin I (cTnI), is a critical regulatory protein in 
the contraction and relaxation of cardiac muscle, linking calcium to bind to the thin filament. 
It has become apparent that myofilament proteins and intracellular calcium availability have 
an effect on the dynamic modulation on contractile function. The phosphorylation of cTnI at 
specific serine and threonine residue sites is an important physiological mechanism for altered 
myofilament functional properties and may play a significant role in the contractile 
dysfunction observed in diabetes. It is possible that exercise might reverse myofilament 
dysfunction in the diabetic heart by altering cTnI phosphorylation levels. However, whether 
exercise alters cardiac myofilament proteins in diabetes is unexplored.  
 
This study aimed to investigate the role of cTnI in the diabetic heart and determine the 
effects diabetes and exercise might have on calcium sensitivity and phosphorylation of the 
myofilament protein, cTnI. I hypothesised that myofilament phosphorylation and calcium 
sensitivity are dysregulated in diabetes, which could be mitigated by exercise training.   
 
Left ventricular tissue –from the Zucker diabetic fatty rat, a model of type 2 diabetes, 
was used to measure total cTnI expression and levels of phosphorylation within cTnI. 
Measurements were taken from four groups: non-diabetic sedentary, diabetic sedentary, non-
diabetic trained, and diabetic trained. We measured myofilament calcium sensitivity via 
single-cell contractility experiments and quantified the level of phosphorylation of cTnI via 
Western blot experiments. Rats were randomized to either eight weeks of treadmill running or 
a sedentary intervention. This combination of experiments allowed us to determine whether 




Western blot experiments from 12-week old tissue illustrated levels of cTnI 
phosphorylation at serine 150 were decreased in diabetic animals compared to non-diabetic 
littermates (P < 0.05, n = 5). In diabetic samples, phosphorylation at serine 23/24 was 
increased (P < 0.05, n = 10), however phosphorylation at threonine 143 (P = 0.21, n = 5) 
showed an increasing trend but did not reach significance. Single-cell contractility 
experiments revealed a leftward shift in the calcium-binding curve of diabetic trained 
cardiomyocytes, indicating an increase in calcium sensitivity compared to non-diabetic 
trained cardiomyocytes; however, the results were not significant. Immunoblots from 20-
week old tissue revealed that cTnI phosphorylation at serine 23/24 (P < 0.05, n = 6) and 
threonine 143 (P < 0.05, n = 6) were significantly decreased in trained diabetics compared to 
trained non-diabetics, corresponding to an increase in calcium sensitivity.  
 
Our results demonstrate that diabetes dysregulates phosphorylation of the myofilament 
protein, cTnI. Whereby, this relationship was altered in trained diabetic rats, showing exercise 
reversed the levels of phosphorylation observed at 12-weeks of age. This thesis has provided 
a deeper insight into the critical role that cTnI phosphorylation (at numerous amino acid 
residues) plays in the altering of single-cell functionality in the diabetic heart and its ability to 
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1.1  Diabetes Mellitus 
1.1.1 Characterisation of Diabetes Mellitus 
Once a disease prominent amongst only affluent adult populations, diabetes mellitus 
has spread beyond its traditional confines, now encompassing the poor and, due to 
increasingly high rates of child obesity, adolescent populations. Diabetes is a chronic, 
metabolic disease characterised by hyperglycemia due to the result of defective insulin 
secretion or insulin sensitivity (Mellitus, 2005). There are several types of diabetes, type 1 
diabetes, gestational diabetes and, the focus of this thesis, type 2 diabetes. Type 2 diabetes 
describes defects in insulin secretion caused by dysfunctional pancreatic ß-cells and insulin 
resistance in target organs (Chatterjee et al., 2017).  
 
1.1.2 Prevalence of Diabetes Mellitus 
The prevalence of diabetes globally is continuously rising, showing a four-fold 
increase in diagnosis numbers from 1980 to 2014 (Zhou et al., 2016). According to the 
International Diabetes Federation, approximately 463 million adults are living with diabetes, 
and this number is expected to exceed 700 million individuals, by 2045 (Williams et al., 
2019). In New Zealand, it was estimated that in 2017/2018, 253, 000 individuals had diabetes 
(Ministry of Health, 2019). In particular, type 2 diabetes affects approximately 90% of 
diabetes cases (Williams et al., 2019). The reality whereby such a large proportion of the 
population has type 2 diabetes should arguably come as no surprise, especially considering 




1.1.3 Heart Disease and Mortality of Diabetes Mellitus 
Chronic hyperglycemia can have detrimental effects throughout several organ systems 
of the body, manifesting in complications such as neuropathy, retinopathy, nephropathy and 
most important to this review, cardiovascular disease. In 1972 it was first identified that 
diabetic patients had increased risk of cardiomyopathies independent of other risk factors, 
including hypertension, high serum cholesterol levels, age, and weight (Rubler et al., 1972). 
Likewise, confirmed in the Framingham study, diabetic patients appeared to be two to five 
times greater at risk of developing cardiomyopathies than their counterparts (Kannel & 
McGee, 1979).  
Currently, literature tends to agree that a significant cause of mortality and morbidity 
in patients with type 2 diabetes is cardiovascular disease (Gu et al., 1998). This mortality and 
morbidity are commonly attributed to the reduction in contractility of the left ventricle as a 
consequence of type 2 diabetes (Jweied et al., 2005; Baldi et al., 2006). At present, the 
diabetic heart phenotype is defined as the existence of abnormal myocardial structure and 
function in the absence of other commodities, such as coronary artery disease and 
hypertension (Boudina & Abel, 2007). Moreover, data indicates that the prevalence of type 2 
diabetes is increasing rapidly (Williams et al., 2019); thus, illustrating the need to further 
focus our efforts on unravelling the underlying mechanisms. 
 
1.2 Cardiac Structure and Calcium Signalling 
1.2.1 Basics of Heart Function 
The heart is an intermittent muscular pump, divided into four chambers; left and right 
atrium, and left and right ventricle. The right ventricle pumps blood to the lungs, while the 
left ventricle simultaneously pumps blood to the rest of the body.  
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With every heartbeat, cells in the body are provided with sufficient levels of oxygen as 
a consequence of the ventricles ejecting blood into circulation pathways of the body (Bers, 
2002). Cardiac output, a product of stroke volume (the amount of blood ejected per heartbeat) 
and heart rate, relies on the systolic (contracting) phase of the cardiac cycle, and the diastolic 
(relaxation) phase of the cardiac cycle. The diastolic phase becomes more significant due to 
its ability to increase end-diastolic volume during stress, for example, which occurs with 
exercise (van der Velden, 2011). One key mechanism for controlling contraction and 
relaxation of the heart is regulating the availability or amount of intracellular calcium (Ca2+) 
present.  
 
1.2.2 Excitation-Contraction Coupling 
Cardiac excitation-contraction coupling is the process of electrical excitation of the 
myocyte to contraction of the heart (Figure 1.1) (Bers, 2002). As a second messenger, Ca2+ is 
essential for cardiac electrical stimulation, resulting in a contraction by activating the 
myofilaments. Evidence suggests that Ca2+ mishandling is a common trigger for both 
contractile dysfunction and cardiovascular diseases (Antoons et al., 2002).  
Upon the depolarisation of the cardiomyocytes, Ca2+ enters the cell through L-type 
Ca2+ channels, triggering the opening of the ryanodine receptor which releases Ca2+ from the 
sarcoplasmic reticulum. The intracellular Ca2+ concentration ([Ca2+]i) increases, allowing 
Ca2+ to bind to the myofilament protein troponin C, initiating myofilament contraction 
through conformational changes in myofilament structure (Figure 1.1). Relaxation of the 
cardiomyocytes occurs when the [Ca2+]i decreases drastically, allowing Ca2+ to dissociate 
from troponin C via removal of Ca2+. This occurs primarily through the reuptake of Ca2+ into 




1.2.3 Cardiac Muscle 
The heart is made up of cardiac muscle tissue, which consists primarily of cardiac 
myocytes. Myocardial tissue is striated, as a result of the regular arrangement of contractile 
proteins, thin actin and thick myosin filaments arranged in functional units called sarcomeres. 
These contractile proteins in the cardiomyocytes interact due to an ‘unlocking’ mechanism, 
providing them with the ability to generate force and contraction. The principal regulator of 
muscle contraction is one of the components of the thin filament called the troponin complex; 
made up of troponin C (TnC), troponin T (TnT), and troponin I (TnI) (Figure 2). The 
inhibitory unit of the troponin complex is the thin filament protein TnI, which acts to inhibit 
actomyosin interactions at diastolic levels of intracellular Ca2+. The elevation of Ca2+ in 
Figure 1.1. Schematic of Ca2+ homeostasis and excitation-contraction coupling. An action potential is fired as myocytes 
are excitable which triggers the depolarization of the sarcolemma along its t-tubules. This triggers inward Ca2+ influx 
through LTCCs, leading to the opening of ryanodine receptor (RYR2) channels by a Ca2+-induced-Ca2+-release process, 
resulting in Ca2+ release from the sarcoplasmic reticulum (SR). This Ca2+ release binds to the actin filament, facilitating the 
formation of cross-bridges and muscle contraction. Relaxation occurs when Ca2+ is re-up taken into the SR and is extruded 
from the cell by the sarcolemma Na+ and Ca2+ exchanger (NCX). (Adapted from Bers, 2002). 
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systole relieves the inhibitory influence of cardiac troponin I (cTnI) through binding to TnC, 
thus stimulating an actomyosin cross-bridge contraction. 
 
Tropomyosin wraps around the actin filaments, blocking the myosin-binding sites and 
is associated with the troponin complex (Figure 1.2). The binding of Ca2+ to TnC allows for 
the tropomyosin-troponin complex to shift off the actin filament allowing myosin to bind to 
the thin filament, resulting in the contraction (Figure 1.3). Once Ca2+ dissociates from TnC 
tropomyosin wraps itself around the actin again blocking the myosin-binding sites, and the 
sarcomere relaxes. Lastly, besides Ca2+, the availability of ATP for ATP-hydrolysis is also a 
regulatory mechanism of contraction (Li et al., 2003). 
Figure 1.2. Structural view of the cardiomyocyte. This figure illustrates how cardiomyocytes contain thin filaments 
consisting of actin monomers and thick filaments consisting of myosin and myosin heads. Tropomyosin wraps around the 
actin filaments and is associated with a complex of three troponins; troponin I (TnI), Troponin C (TnC), and troponin T 
(TnT). The binding of Ca2+ to TnC allows for the tropomyosin-troponin complex to shift off the actin filament. Myosin can 





Figure 1.3. Schematic drawing of a myocardial contraction. This diagram shows the actin filaments sliding past the myosin 
filaments towards the middle of the sarcomere, forming a cross-bridge cycle. This action results in the muscle contracting 
during systole. (Original figure Gold, 2020). 
 
1.2.4 The Effects of Diabetes on the Contractility of the Diabetic Heart 
Heart patients with diabetes frequently have an impaired left ventricular function 
relative to non-diabetic patients (Group, 2013). Consequently, a normal healthy lifestyle is 
compromised due to the increased stiffness and diastolic dysfunction of the left ventricle, 
followed by systolic impairment, resulting in the inability of type 2 diabetics to increase 
systolic function during exercise or other stressors (Baldi et al., 2016). Consistent results from 
research using diabetic (db/db) mice as a model of type 2 diabetes show that when measuring 
contractile performances of perfused Langendoff hearts and Ca2+ transients using isolated 
cardiomyocytes, these resulted in a reduction in both the peak rate of force production and 
total force production (Belke et al., 2004; Stolen et al., 2009). These investigations support 
the idea that in diabetic cardiomyopathy, intrinsic alterations of cardiac myocytes are 
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impairing the heart’s ability to relax which likely represents the initial stage of diabetic 
cardiomyopathies. 
In pursuit of understanding the underlying pathogenesis of cardiovascular diseases, 
research (Diffee et al., 2001) has revealed that Ca2+ sensitivity is critical for the force 
generation of the left ventricle. Comparisons of left ventricular cells from heart patients with 
and without type 2 diabetes suggest that diabetic cardiomyocytes have reduced Ca2+ 
sensitivity (Jweied et al., 2005). It was thought that to increase the cardiac contractility, a 
drug that increased [Ca2+]i through eliciting a sequence of events involving cAMP was 
necessary. New insights show that these drugs generally fail to increase contractility in 
diabetic patients, suggesting that the reduced Ca2+ availability is not the underlying problem 
(Malik et al., 2011).  
At present, there is a lack of work testing diabetes-specific changes in the 
cardiomyocyte contractile apparatus even though diabetic myofilament function might be a 
novel therapeutic target (reviewed by Baldi et al., 2016).  
 
1.3 Post-translational Modifications 
1.3.1 Post-translational Modifications Affect Heart Function 
Myocardial contractility represents the innate ability of the heart muscle to eject a 
stroke volume at a given afterload and preload. At the cellular level, the determinants of 
contractility are the generation of tension and shortening capabilities of the sarcomere through 
cross-bridge kinetics as controlled by Ca2+ activation, the rate of cross-bridge turnover, and 
the relative Ca2+ response in the sarcomere. Post-translational modifications are changes to a 
protein following translation whereby the addition of functional groups or proteins, 
proteolytic cleavage of regulatory groups, or the degradation of proteins can be the 
explanation of protein regulation of acute changes in disease susceptibility (McLarty et al., 
 
 8 
2013). In the heart, post-translational modifications can alter myofilament function, 
specifically the ability of Ca2+ to bind to TnC. One common type of post-translational 
modification is phosphorylation, a reversible reaction that occurs as a consequence of protein 
kinases and the addition of a phosphoryl group (Figure 1.4) (Rodney, 2006). Altered 
phosphorylation at myofilament proteins affects Ca2+ sensitivity in other aetiologies of heart 
failure (Marston & de Tombe, 2008).  
 Cellular Ca2+ cycling and myofilament properties are under strict control via 
phosphatases and kinases within the hearts muscle cells (Hamdani et al., 2008). Thus, these 
proteins dephosphorylate and phosphorylate target proteins in the myofilament, a pair of 
processes that play a role in the regulation of contraction and relaxation (Neumann et al., 
1997). Phosphorylation of troponin is suggested to change Ca2+ affinity in other forms of 
heart failure (Takeishi et al., 1998; Dong et al., 2012).  In particular, troponin is of interest to 
this review due to several works showing the functional significance of phosphorylation of 





Figure 1.4. Phosphorylation mechanism. The left panel shows the reversibility of phosphorylation, a post-translational 
modification, regulating protein function. Protein kinases mediate phosphorylation at specific side chains, and phosphatases 
reverse protein phosphorylation by hydrolysing the phosphate group. The right panel shows that the addition of a phosphate 
group causes a conformational change in proteins that either activates or deactivates protein function. (Adapted from 
ThermoFisher Sci). 
 
1.4 The Myofilament Underlies Changes to Contractility 
1.4.1 Cardiac Troponin I and the Myofilament 
 At present, cTnI is a crucial regulator of cardiac muscle contraction and relaxation. 
This is commonly attributed to the Ca2+ sensitivity of the myofilament being governed by the 
expression of cTnI of the cardiac myofilament (Layland et al., 2004). Conversely, variations 
in contractility of the myocardium can be a result of changes to the Ca2+ transient size or 
duration. Despite this, evidence from mice treated with gene-targeted ablation of cTnI 
demonstrated a reduction in myofilament Ca2+ sensitivity, diastolic dysfunction and the 
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development of heart failure (Huang et al., 1999). This work suggests the importance of cTnI 
in health and disease. 
 
1.4.2 Phosphorylation of Cardiac Troponin I 
 cTnI function is altered by PTMs such as phosphorylation and O-GlcNAcylation. The 
phosphorylation of cTnI at specific serine (Ser) and threonine (Thr) residues underpins the 
mechanisms through which myofilament properties are altered (Figure 1.5B). These 
modifications in cTnI phosphorylation status could reflect changes in the balance between 
kinases and phosphatases, with altered expression being reported in failing hearts (Bodor et 
al., 1997a; van der Velden et al., 2003). Predominantly, 𝛽-adrenergic stimulation promotes 
cAMP-dependent protein kinase A (PKA)-mediated phosphorylation of cTnI. This stimulates 
an increase in the circulatory system, often altering the properties of the cardiac myofilament 
proteins, including myofilament Ca2+ sensitivity, to meet the physiological demands of 
stressors, through positive inotropic and lusitropic effects (Layland et al., 2005).  
 
 Myofilament Ca2+ sensitivity (often expressed as pCa50) is a functional measurement 
that indicates the necessary Ca2+ concentration within the cytosol required to generate 50% 
maximal tension, which models physiological Ca2+ levels during systole. For example, PKA-
mediated phosphorylation of the myofilament decreases pCa50 and increases maximal tension 
(Zhang et al., 1995; Pi et al., 2003), essential factors of cardiac contractility.  
 
A common finding in the literature investigating Ca2+ sensitivity in human 
cardiomyocytes is increased Ca2+ sensitivity is associated with diseased samples compared to 
control sample obtained from organ donors (Bodor et al., 1997a; van der Velden et al., 2003). 
The increase is pCa50 in diseased hearts has been found to be associated with low cTnI 
 
 11 
phosphorylation. Previous studies have linked amino acid residues within cTnI with increased 
Ca2+ sensitivity in the failing heart, including PKA sites Ser23/24 (Messer et al., 2007), PKC 
sites Thr143 and Ser43/45 (Wijnker et al., 2014), and AMPK sites Ser150 (Sancho Solis et 
al., 2011) (Figure 1.5A). It has been strongly suggested in the literature that these 
phosphorylation sites either contribute to or attempt to compensate for, the altered 
myofilament functioning in failing cardiomyocytes (van der Velden et al., 2003).  
 
There is a growing body of literature that recognises phosphorylation of myofilament 
proteins in heart failure (Marston & de Tombe, 2008) and its role in modulating myofilament 
Ca2+ sensitivity (Layland et al., 2005). However, few studies have investigated the effects 
phosphorylation may have on the diabetic heart. In a streptozotocin (STZ) mouse model of 
diabetes, Jweied and colleagues found that cTnI and cTnT phosphorylation was augmented 
but could not correlate these findings with Ca2+ sensitivity (Jweied et al., 2005). Although this 
study was completed in a mouse model and not human, the results indicate that 
phosphorylation might contribute to the functional changes occurring in the diabetic heart. In 
the STZ rat model of diabetes, augmented pCa50 corresponded with no change in the amount 
of phosphorylation at key myofilament functional proteins like myosin-binding protein C and 
myosin regulatory light chain 2 (Falcao-Pires et al., 2011). However, in the same rats, results 
indicated there was significant compensation for metabolic changes, further contributing to 
the decreased contractility measured. To date, there is still work needed to assess both 
phosphorylation status and function in skinned cardiomyocytes in the Zucker diabetic fatty 
(ZDF) rat model of diabetes.  
 
As previously mentioned, kinases and phosphatases are responsible for 
phosphorylation activity, and the mechanisms that underpin this may lead to 
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hyperphosphorylation or hypophosphorylation in the diabetic heart. For example, β-
adrenergic receptor (β-AR) protein expression is reduced in the ZDF heart (Haley et al., 
2015), suggesting a reduction in PKA mediated phosphorylation in the ZDF heart. 
Additionally, extensive research has shown that PKC phosphorylation is increased in diabetic 
hearts (Malhotra & Sanghi, 1997; Ahmad et al., 2005), and that PKC phosphorylates cTnI 
and cTnT (Noland et al., 1995). Collectively, there appears to be a plethora of evidence 
demonstrating phosphorylation of myofilament proteins, including cTnI, contribute to 
myofilament dysfunction, and together affect organ-level dysfunction of contractility in the 
diabetic heart.  
 
 
Figure 1.5. Structural view of the cTnI. (A) Position of cTnI phosphorylated Ser (S), and Thr (T) residues. (B) Structural 
model of cTnI, troponin T (TnT), and Troponin C (TnC) showing the location of phosphorylation sites. (Adapted from Takeda 
et al., 2003). 
 
Based on previous research, the phosphorylation of cTnI at Ser23/24, Thr143 and 
Ser150 are ideal candidates for the investigation of altered myofilament properties in diabetic 




1.4.3 Troponin and the Diabetic Heart 
 A common characteristic of type 2 diabetes is the progressive development of a 
cardiovascular disease, commonly manifesting as an impairment in diastolic performance 
(Baldi et al., 2006). The intrinsic properties of the myofilaments appear to be altered 
(Malhotra & Sanghi, 1997), in particular, the myofilament Ca2+ sensitivity. Although Ca2+ 
sensitivity research has been implicated in non-diabetic patients with heart failure (Bilchick et 
al., 2007), research is just beginning to be thoroughly done in the diabetic heart. In heart 
failure, initial studies isolating cells from end-stage failing hearts showed alterations in Ca2+ 
sensitivity (van der Velden et al., 2003). These changes in myofilament Ca2+ sensitivity have 
been linked to post-translational modifications including defects in the 𝛽-adrenergic 
signalling pathway due to a reduction in phosphorylation of PKA protein targets (Bodor et al., 
1997b), previously described in the above section. Alongside reduced PKA-mediated protein 
phosphorylation, numerous myofilament protein modifications have been reported, which 
may be the underlying cause of impaired diastolic function of the heart (Wijnker et al., 2011; 
Wende, 2016). The post-translational modifications, such as phosphorylation, and O-
GlcNAcylation, show alterations within the diabetic heart.  
 
Although studies identifying reduced Ca2+ sensitivity in type 2 diabetics is limited, 
research has been carried out in human biopsies and type 1 diabetic rat models. In the diabetic 
heart, the most common finding is reduced Ca2+ sensitivity (Jweied et al., 2005) tested using a 
methodology involving skinned cells attached to a force transducer measuring force generated 
in different concentrations of Ca2+. Jweied et al. (2005) used human myocardial biopsies, of 
which patients were diabetic and non-diabetic. Their study assessed for myofilament function 
using the skinning methodology and their results showed a decreased Ca2+ sensitivity, that is, 
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a depressed myofilament function, associated with the diabetic patients. Their results 
demonstrated that cTnI and TnT might be constitutively phosphorylated in the diabetic heart; 
thus, myofilament function and Ca2+ sensitivity might be expected to be depressed.  
Despite these results, when considering the ZDF rat model of diabetes, pCa50 was not 
different between non-diabetic and diabetic ZDF rats at 16 weeks of age (van den Brom et al., 
2009). Regardless of the lack of a pCa50 difference between groups, diabetic ZDF rats had a 
reduced rate of cross-bridge cycling, which might explain, in part, the myofilament functional 
changes leading to these rats impaired diastolic and systolic functioning. Indicating that the 
diastolic and systolic dysfunction present early in the ZDF rat, may not be due to altered Ca2+ 
sensitivity, but instead, a result of other functional parameters associated with the maximal 
force generated or the rate of cross-bridge cycling. Nevertheless, the conflicting data within 
the diabetic heart and Ca2+ sensitivity emphasize the need for more studies to better 
understand the cause or the adaptations of the disease.   
 
1.5 Exercise Recommendations and Lifestyle Interventions 
1.5.1 Physical Activity  
 It is widely agreed that regular physical activity is a fundamental component of a 
healthy lifestyle (Pate et al., 1995). Physical activity can be defined as “any bodily movement 
produced by skeletal muscles that result in energy expenditure” (Caspersen et al., 1985). Over 
25 years ago, the American College of Sports Medicine issued physical activity guidelines to 
clarify the regulatory and intensity to improve health, lower susceptibility to diseases and 
decrease rates of early mortality. They quantified the intensity of physical activity as 
metabolic equivalents or METs and recommended moderate-intensity activity per day, which 
equates to an activity performed with a 3-6 METs intensity. Regardless of the scientific 
evidence linking physical activity to health benefits, (Kannel & McGee, 1979), as well as the 
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apparent public acknowledgement surrounding the importance of physical activity, millions 
of individuals remain sedentary. Several clinical trials have confirmed the effects of regular 
exercise on patients with chronic heart failure, showing it can improve the prognosis of these 
patients including improvements in cardiac structure and function (Cassidy et al., 2016), 
reduced cardiovascular risk (Morris & Crawford, 1958), increase longevity (Lee et al., 2017), 
and increased quality of life (Antonicelli et al., 2016). 
 
1.5.2 Exercise as an Intervention 
It is well-established that exercise training status and exercise capacity predict the risk 
of cardiovascular disease and mortality (Myers et al., 2002). Multiple studies, including the 
Framingham Study, the Harvard Alumni study, and the Lipid Research Clinics Trial all 
demonstrated that exercise testing provides the ability to determine mortality rates, as there is 
a graded inverse relationship between total physical activity and mortality. It has been proven 
through research that poor physical fitness is modifiable, and overtime increased exercise 
capacity has demonstrated improved prognostics of cardiovascular diseases and diabetes (Pate 
et al., 1995). Observations of treadmill running have shown that for every 1-MET increase in 
performance, there is a resulting 12% improvement in survival in patients with or without 
cardiovascular disease (Myers et al., 2002). Other studies such as The Dallas Bed Rest and 
Training Study are contributing to this growing body of evidence, demonstrating that regular 
exercise training increases aerobic capacity (VO2max), stroke volume and cardiac output in 
deconditioned individuals (Saltin et al., 1968). Despite this, the specific cellular alterations 




1.5.3 Diabetes and Exercise 
Individuals with type 2 diabetes often present with lower VO2max when compared to 
non-diabetic individuals (Baldi et al., 2003). However, literature comparing the oxygen 
extraction in diabetics and non-diabetics is both limited and with contradictory results (Baldi 
et al., 2006; Mac et al., 2011). Nevertheless, the literature agrees that a reduction in 
exercising cardiac output is characteristic of individuals with type 2 diabetes (Baldi et al., 
2003; Baldi et al., 2010; O'Connor et al., 2015). Similar to that of a healthy individual, a 
diabetic’s resting cardiac output remains identical to that of a non-diabetic individual. Patients 
with type 2 diabetes do, however, typically achieve this similar cardiac output with a faster 
heart rate and lower left ventricular stroke volume than a non-diabetic individual (Baldi et al., 
2003; Pinto et al., 2014). During exercise, a diabetic patients heart rate reserve is reduced 
(Mac et al., 2011) and their left ventricular stroke volume either increased slightly or not at all 
(Baldi et al., 2006). These factors influence the oxygen-carrying capacity, which ultimately 
affects the VO2 max of an individual with type 2 diabetes or the ability to reach higher 
workloads.  
 
Exercise has been well established as an intervention for cardiovascular disease, 
primarily focusing on the lifestyle adaptations with physical activity as the target in mind 
(Lear et al., 2017). Diffee et al. (2001) trained rats to undergo a progressive treadmill running 
protocol for 11 weeks and performed experiments on chemically skinned myocytes to 
determine the force and Ca2+ sensitivity of the myofilaments. The results indicated that the 
heart responds to exercise training in ways that increased Ca2+ sensitivity.  
Subsequently, regular endurance exercise training elicits positive adaptations of 
cardiac function that enhance the cardiovascular system by improving the maximal and 
submaximal performance of the left ventricle (Diffee & Nagle, 2003), due to the improvement 
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of the intrinsic contractility of the myocardium (Diffee et al., 2001). Thus, the effects of 
exercise on the diabetic heart should be tested, as it could prove to improve the contractility of 
the diabetic heart. 
 
1.6 Aims and Hypotheses 
Firstly, this thesis aimed to determine the phosphorylation status of the myofilament 
protein cTnI in ZDF diabetic hearts. Further, we aimed to associate changes in cTnI 
phosphorylation with pCa50. We hypothesized that in ZDF rats’ diabetic hearts, we would 
observe an increase in cTnI phosphorylation at Ser23/24, and Thr143, and a decrease at 
Ser150. We also hypothesized that diabetes would induce a reduction in pCa50 in the ZDF rats 
hearts. 
 
Secondly, we aimed to determine the effects of exercise training on my phospho-state of 
cTnI in non-diabetic and diabetic hearts. We hypothesized that exercise training would 
increase pCa50 in both non-diabetic and diabetic hearts. We also hypothesized that an increase 






2.1 Rat Model of Diabetes 
2.1.1 Zucker Diabetic Fatty rat (ZDF) 
The ZDF rats used in this study are a standard animal model of type-II diabetes (Pang 
et al., 2018). The ZDF rat has a gene coding mutation on the leptin receptor (fa/fa) which can 
lead to obesity and hyperglycaemia when on a high-fat chow diet (Phillips et al., 1996; Pick 
et al., 1998). This genetic modification is considered a model of early-onset diabetes as they 
exhibit hyperglycaemia, hyperinsulinemia, and hypertriglyceridemia conditions at about 12 
weeks of age (Ikeda et al., 1981). Throughout this thesis, homozygous ZDF rats will be 
referred to as diabetic (DM), and the lean rats will be referred to as non-diabetic (nDM). The 
non-diabetic littermates consist of homozygous dominant (+/+) or heterozygous (fa/+) 
genotypes and are normoglycaemic throughout their lifespan. In this study, both 12 and 20-
week-old rats were used to determine cTnI phosphorylation at the initial stages of diabetes 
and cardiac myofilament sensitivity after eight weeks of uncontrolled diabetes.  
 
2.1.2 Animal Handling & Tissue Collection 
Single-cell contractility experiments, and exercising protocols described below were 
all performed by Ms Angela Greenman (A PhD student in the Department of Medicine, 
University of Otago). All procedures and animal handling were conducted with the approval 
of the University of Otago’s Animal Ethics Committee and per the New Zealand Animal 
Welfare Act (1999). All rats were housed in a controlled environment (stable temperature of 
21 ± 1ºC and standard 12-hour light and dark cycle) at the animal holding facility, University 
of Otago, Dunedin. ZDF rats were fed a high-fat Purina 5008 diet (LabDiet, St Louis, MO 
USA) ad libitum and given water ad libitum. 
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Animals were anaesthetised with a lethal dose of sodium pentobarbital (60 mg/kg) 
through intraperitoneal injection. Upon anaesthesia, the final body weight was measured. The 
chest cavity was opened, and the heart was excised promptly and put into a cold (4ºC) 
relaxing buffer (100 mM KCL, 1.75 mM EGTA, 10 mM Imidazole, 4 mM ATP, 5 mM 
MgCl2, pH 7.0 with KOH). The heart was weighed proceeding the removal of excess tissue 
and then dissected into its four chambers and septum. Left ventricle dissection was completed 
in less than six minutes upon opening the chest. The left ventricle was weighed and snap-
frozen in liquid nitrogen prior to other tissues. All tissues were stored at -80 ºC in preparation 
for later use.  
 
2.2 Treadmill Running Intervention 
2.2.1 Randomisation and Familiarisation 
The ZDF rat develops diabetes at ~12 weeks of age but does not develop indices of 
heart failure until week 20. Therefore, we randomly assigned 12-week old rats (diabetic and 
non-diabetic littermates) to either an exercise or sedentary intervention. Each pair had two 
days of acclimatising to the new environment before an initial echocardiography. The rats 
randomised to the exercise intervention experienced a familiarity period with the rodent 
treadmill (Ugo Basile, Figure 2.1) which included three sessions of 10-, 12.5- and 15-minutes 
spread over three different days. To ensure familiarisation, a speed of 5 m/min was used to 
train the rat on how the belt moves. They were also familiarised to a 5% grade which was 







Figure 2.1. Image of the rodent treadmill (left). ZDF rats running without wooden blocks (middle) and, with wooden blocks 
and sponges (right) to motivate the rats and protect their tails from abrasions, respectively. (Greenman, 2020, Unpublished). 
 
2.2.2 Exercise Training 
The 8-week treadmill running protocol progressively increased duration and speed to 
accommodate adaptation to the exercise training. Running duration began at 10 minutes per 
day but increased to a maximum of 40 minutes per day by the fourth training day. Initially, 
the speed was set to 10m/min and progressed to 18 m/min by training day 29. The grade was 
set at 5% throughout the intervention.  
 
2.3 Western Blotting (Immunoblotting) 
Many researchers have utilised the western blot technique to identify and detect protein 
expression. The benefit of this approach is that the different proteins become separated in a 
gel, based on molecular weight (Shapiro et al., 1967). For this project, the proteins were 
separated using sodium dodecyl (SDS) and the polyacrylamide gel electrophoresis (PAGE) 
technique. The expression levels of phosphorylated cTnI residues (Ser23/24, Ser150, and 
Thr143) normalized to total cTnI were investigated from ZDF rats from both diabetic and 
non-diabetic as well as sedentary and exercise interventions. ß-actin was used to ensure equal 
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loading. To visualise the proteins, gels containing the proteins need to be transferred from the 
SDS-PAGE gel to a nitrocellulose membrane, as detailed in section 2.3.6. Once transferred 
onto the membrane, proteins of interest could be visualised via the addition of specific 
antibodies. 
 
2.3.1 Sample Homogenisation 
Prior to left ventricular tissue being placed in a radioimmunoprecipitation assay 
(RIPA) buffer for sample homogenisation, 1% SDS RIPA buffer solution was prepared 
(composition: 50 mM Tris-HCl, 150 mM NaCl, 1% Triton, at pH 7.5), supplemented with 
inhibitors (200 µL 25X cOmplete, 500 µL 20X PhosphSTOP, 55 µL 100 mM PMSF, 400 µL 
10% SDS) to prevent protein degradation. A higher concentration of SDS was required to 
adequately isolate myofilament proteins of interest (i.e., troponin). Left ventricle tissue was 
cut into smaller pieces (~50 mg) and added to glass tubes, ensuring the tissue was fully 
covered by RIPA buffer plus inhibitors solution (~500 µL). The tissue was mechanically 
homogenised on ice by the IKA Ultra Turrax T8 homogenizer at speed 8 for 3 x 30 seconds, 
or until sample appeared completely homogenised. The homogenate was transferred to 
centrifuge tubes and incubated on ice prior to centrifugation (15000 RPM, 15 min, 4ºC). The 
supernatant containing protein was carefully transferred to new Eppendorf tubes, 
appropriately labelled. Protein concentration was determined using Gen5 Take3 protein 
quantification assay from BioTek. Duplicates of ~3 µL of homogenate samples were loaded 
onto the microplate spectrophotometer. Quantification of the protein concentration from the 
sample is estimated by the amount of light absorbed at 280 nm wavelength (Whitaker & 
Granum, 1980). Preceding, protein samples were snap-frozen in liquid nitrogen and stored in 




2.3.2 Sodium Sulfate Poly-Acrylamide Gel Electrophoresis 
SDS PAGE allows for electrophoretic protein separation. SDS is a detergent that 
denatures proteins and polypeptide chains and donates negative charges to give all proteins an 
equal charge (Rath et al., 2009). Moreover, SDS can convert proteins into linear structures of 
different sizes, allowing for the migration of proteins, through the gel, dependent on 
molecular weight (Figure 2.2) as well as facilitating binding to amino acids and giving a 
negative charge to the primary structure. The negative charge is then used with the PAGE 
technique, where the proteins run through the polyacrylamide gel away from the top negative 
cathode towards the bottom positive anode. The migration of the smaller and larger proteins 
can be differentiated through applying an electrical field. Polyacrylamide forms a matrix 
suitable for the separation of proteins of a specific size. The pore sizes in the matrix are 
determined by the percentage of acrylamide in the gels; thus, protein migration is dependent 
on an electrical field and pore size. A protein ladder, with known molecular weights, runs 




Figure 2.2. Schematic representation of protein denaturation by SDS. Proteins are in a folded structure with positive and 
negative charges. In the presence of SDS and a reducing agent that cleaves disulphide binds critical for protein folding, 
proteins unfold into linear chains with negative charges. (The principle and method of polyacrylamide gel electrophoresis 
(SDS-PAGE), n.d.). 
 
2.3.3 Gel Casting 
SDS-PAGE electrophoresis was carried out using the Mini-Protean III system 
(BioRad, UK). Here, 15% polyacrylamide resolving gels and 4% polyacrylamide stacking 
gels were prepared according to Table 2.1, using glass plates (BioRad, UK) with 1.5 mm 
spacers (BioRad, UK). To ensure the gel would mould correctly, the cast was filled with 






Table 2.1: Components for 15% resolving gel and 4% stacking gel. The volumes used for each component of a 1 x 1.5mm 
gel for SDS-PAGE experiments. 
Components Resolving gel 15% 
(µL) 
Stacking gel 4% 
(µL) 
Milli-Q H2O 2832 2516 
1.5M Resolving Buffer (375 mM 
Tris, pH 8.8) 
2000 N/A 
0.5M Stacking Buffer (125 mM 
Tris, pH 6.8) 
N/A 1000 
40% Acrylamide  3000 400 
10% SDS 80 40 







Initially, a 15% resolving gel was cast, with an additional water layer added to remove 
air bubbles and prevent evaporation. The gel was left to polymerise for 1 hour at room 
temperature (RT). Once set, the overlying water layer was removed, and a 4% stacking gel 
was loaded on top of the resolving gel, and a 15 well comb was inserted to form the loading 
wells (Figure 2.3). The stacking gel was left to set for 1 hour. The plates containing the gels 
were inserted into the running tank, immersed in 1x running buffer (25 mM Tris, 192 mM 





Figure 2.3. Structural view of the SDS-PAGE gel. (Gold, 2020, original figure). 
 
2.3.4 Sample Preparation 
A protein quantity of 20 µg/lane was chosen for this study. A total of 10 µL was 
loaded per lane, which consisted of 20 µg of protein per sample, a final concentration of 1X 
sample buffer (31.25 mM Tris pH 6.8, 10% glycerol, 2% SDS, 500 mM DTT, 0.01 mM 
Bromophenol blue) and water adjusted to make up the final volume. Following, the samples 
were heated to 90ºC for 5 minutes to ensure protein denaturation and then centrifuged (13500 
RPM for 0.5 minutes) to collect the sample at the bottom of the Eppendorf tube. Samples 
were kept on ice before loading.  
 
2.3.5 Protein Separation 
Precision protein plus dual colour standard (Bio-Rad) also referred to as the molecular 
weight marker, was loaded into the first well from the left used to monitor the progress of the 
protein migration. Laemmli-diluted samples were loaded (10 µL/lane). An electrical field 
(120 V, ~75 minutes) was applied to the gel until the bromophenol blue (leading dye) was 




2.3.6 Wet-Tank Transfer from the gel to a membrane 
In this experiment, a BioRad Transfer Unit was used to transfer proteins onto a 
nitrocellulose membrane. The resolving gel was separated from the stacking gel and placed 
on top of the membrane, sandwiched between pre-cut filter paper and sponges on either side 
of the sandwich (Figure 2.4). Prior to the formation of the transfer sandwich, filter papers, 
sponges and nitrocellulose membranes were soaked in 1x transfer buffer (192 mM Glycine, 
25 mM Tris). Between the addition of each component of the transfer sandwich, a roller was 
run to remove any potential air bubbles that could confound the transfer. Lastly, the transfer 
buffer was poured into the transfer tank, and the cathode lid was placed on top. The gels were 
run with an Amersham™ Electrophoresis Power Supply – EPS 301 (GE Healthcare, 
Buckinghamshire, UK) for 3 hours at 100 V, located in the cold room (4ºC). This moved 
proteins from the gel to the membrane, where they became attached and immobilised.  
 
 
Figure 2.4. Schematic view of the membrane transfer 'sandwich' used in a wet-transfer. The ‘sandwich’ facilitates the 
migration of the negatively charged proteins towards the positive anode from the polyacrylamide gel onto the nitrocellulose 




2.3.7 Membrane Blocking and Probing with Antibodies 
After the transfer was complete, the nitrocellulose membrane was blocked in 5% 
skimmed milk dissolved Tris-buffered saline (1x TBST: 150 mM NaCl, 50 mM Tris, 0.05% 
Tween-20, pH 7.6), to prevent non-specific binding of the antibodies.  
Hereafter, the membrane was cut horizontally, guided by the protein ladder to liberate 
the bottom containing cTnI (~28 kDa), and a top portion where 𝛽-actin (~42 kDa) was 
present. Once the membrane was cut, the bottom membrane was probed with its respective 
primary antibodies (dilutions are shown in Table 2.2) overnight (4ºC, on the rocker). The 
following morning, the top membrane was probed with its respective primary antibody for 1 
hour (RT, on the rocker). After treatment, the membranes underwent 4 x 5-minute washes in 
TBST; this ensured that unbound antibodies were removed to reduce background hence 
increase the signal to noise ratio. Primary antibodies recognise and bind to the protein of 
interest, and the secondary antibody binds to the primary antibody (Figure 2.5).  
 
 
Figure 2.5. Schematic diagram of probing the membrane with primary and secondary antibodies. Following blocking the 
membrane, it is probed with a primary antibody (blue) and then a secondary antibody (red). (Gold, 2020, original figure). 
 
The bottom membrane was incubated in its respective secondary antibody (dilutions 
are shown in Table 2.3) for 1 hour (RT, rocker). Secondary antibodies tagged with 
horseradish peroxidase (HRP) were used to bind to the primary antibody, thus allowing 
protein detection (Figure 2.5). The top membrane did not require a secondary antibody for the 
detection of 𝛽-actin because the primary antibody is HRP conjugated. Following 
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administration of the necessary antibodies, the membranes underwent 4 x 5-minute washes, in 
TBST again.  
 
Table 2.2. Summary of primary antibodies used, with dilutions factors and incubation periods for related experiments. 
Primary 
Antibody 
Total cTnI Ser23/24 Ser150 Thr143 𝛽-actin 
Dilution 
factor 
1:1000 1:1000 1:1000 1:1000 1:25,000 
Dilution 
solution 


















Abcam Abcam Abcam 
 











Dilution factor 1:25,000 1:25,000 1:25,000 1:25,000 
Dilution solution TBST TBST TBST TBST 
Incubation 
conditions 
1hr, RT 1hr, RT 1hr, RT 1hr, RT 
Manufacturer Abcam Abcam Abcam Abcam 
 
2.3.8 Protein Detection by Enhanced Chemiluminescence (ECL) 
After washing the membrane, it was re-orientated onto cling film on a flat surface. An 
equal mixture of Reagent A (2 mL) and Reagent B (2 mL) from the Clarity ECL Western Blot 
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Detection Reagents (Bio-Rad, UK) were mixed and pipetted onto the membrane to fully 
cover it and left to sit for 5 minutes at RT. The membrane was then placed between two 
sheets of transparent plastic. HRP catalyses the oxidation of luminol resulting in the light to 
be released and captured by the SYNGENE PXi machine (Figure 2.6). Varying exposure 
times were required to optimise band intensity. Captured images were saved and transferred 
to a computer for band quantification using Genetools (version 4.3.10).  
 
 
Figure 2.6. Schematic diagram of the chemiluminescence method. A reaction mixture is added to the membrane. The 
enzyme (yellow) attached to the antibody catalyses a reaction that emits light, this is detected by a camera. (Gold, 2020, 
original figure). 
 
2.3.9 Densitometry  
Using image analysis software Genetools (version 4.3.10), a rectangle was placed 
around the bands of interest, and the software automatically identified the lanes and their 
respective bands. Densitometry analysis was carried out by normalising the densities of the 
protein bands of interest to the loading control, 𝛽-actin. This was done to account for any 
potential errors that could have occurred while loading proteins into the SDS-PAGE gels. In 
experiments analysing specific phosphorylation sites, the density of protein was normalised to 
the total cTnI protein expression. 
 
2.3.10 Stripping 
When probing for specific cTnI phosphorylation sites, a stripping protocol was utilised. 
Following the imaging of the blot for total cTnI protein expression, it was stripped of that 
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antibody using a Stripping Buffer (100 mM 𝛽-Mercaptoethanol, 2% SDS, 62.5 mM Tris) for 
45 minutes at 50ºC. The membrane underwent 4 x 5-minute washes each in TBST, followed 
by imaging for 10 minutes using the SYNGENE PXi machine to ensure the cTnI antibody 
had been removed. Once confirmed, the membrane was blocked in 5% skimmed milk 
dissolved Tris-buffered saline for an additional 1 hour, rinsed with TBST and incubated with 
the phospho-specific antibody of interest (see Table 2.2) overnight. Sections 2.3.7, 2.3.8, and 
2.3.9 were repeated as described above.  
 
2.4 Single-cell Isolations and Calcium Sensitivity Testing 
2.4.1 Extraction and Permeabilization of Skinned Cardiomyocytes 
Left ventricle samples that had previously been frozen were partially homogenised in 
~500 µL relaxing buffer with HALT Protease and Phosphatase Inhibitor Cocktail 100X 
(Thermo Scientific, 78430). The myocyte suspension was centrifuged at 10, 000 RPM, re-
suspended and permeabilised with 1.1% Triton X-100 (Thermo Scientific) for 8 minutes. This 
resulted in a pellet of skinned myocytes that were washed with relaxing buffer three times. 
Myocytes were stored on ice and used for up to two days. 
 
2.4.2 Selecting and Gluing the Skinned Cardiomyocytes 
A drop of cell suspension was put on a coverslip and placed on top of a glass slide on 
an inverted phase-contrast microscope (Nikon). The single cardiomyocyte or small bundle of 
cells (approximately two to five cells) being analysed were then chosen based on good 
striation pattern and size. It was then aligned with the needle tips of the piezoelectric motor 
and a force transducer (Aurora Scientific, 405 model). A thin layer of silicone glue 
(Marineland Aquarium Sealant) was placed on the tips of the force-transducers which were 
immersed into the drop of cell suspension and attached to the ends of the cardiomyocyte to 
 
 31 
create a glue halo around both ends. Once the tips were in position using motorised 
micromanipulators, they were put down so that they were glued to the extremity of the 
cardiomyocyte and left there for 10 minutes. After the cardiomyocytes were securely 
mounted, they were lifted slightly to make sure the force transducers did not stick to the 
coverslip. The glue was left to cure for a further 30 minutes at a set temperature of 15ºC. 
Once fixed, the cell could be moved into the well containing the lowest concentration of Ca2+ 
(pCa 9.0) and stretched until the sarcomere length was equivalent to 2.3 µm (Figure 2.7). 
Sarcomere length, cell length and cell width were visualised and measured using an IDS 
camera and VSL 900B software (Aurora Scientific). The experimental set-up was placed on 
top of a floating table (TMC, USA) to reduce noise. 
 
 
Figure 2.7. Image of the Ca2+ concentration bath apparatus. A schematic diagram of an isolated cardiomyocyte, stretched 
to 2.3µm when glued to the piezoelectric motor and a force transducer. (Greenman, 2020, Unpublished). 
 
2.4.3 Recording Force Measurements of Active, Passive and Calcium Sensitivity 
The cardiomyocyte was gently moved into baths containing different concentrations 
of Ca2+ to develop myofilament tension. To measure the force at a given pCa, the myocyte 
was slacked by 20% of its original length (slack test) upon force plateau (Figure 2.8). The 
change in force from peak length to 80% of its initial length gave a measurement of force as a 
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given pCa. Initially, force was measured in a Ca2+ concentration bath of 4.5 and then 
randomly selected submaximal Ca2+ concentration solutions, with every fourth or fifth 
activation performed in the 4.5 solution to assess any decline in myocyte performance. 
Submaximal Ca2+ concentration solutions were made by mixing different ratios of Ca2+ 
concentration solutions 9.0 (7.0 mM EGTA, 20.0 mM Imidazole, 5.42 mM MgCl2, 79.16 mM 
KCL, 16.33 µM CaCl2, 14.5 mM CrP, 4.74 mM ATP, pH 7.0 with KOH) and 4.5 (7.0 mM 
EGTA, 20.0 mM Imidazole, 5.26 mM MgCl2, 64.0 mM KCL, 7.01 mM CaCl2, 14.5 mM CrP, 
4.81 mM ATP, pH 7.0 with KOH), determined from the computer program Fabiato (Fabiato, 
1988). The experimenter was blinded to disease-state or intervention assignment of a given 
left ventricle sample to avoid any bias when choosing to slack the cell. Myocytes were 
excluded from the data analysis if 80% of their maximal force was not maintained by the end 
of the protocol. 
 
 
Figure 2.8. Schematic diagram of slacking a cardiomyocyte. Cardiomyocytes are stretched to a sarcomere length of 2.3µm, 





2.4.4 Calculations of Active Tension 
Active tension was calculated by subtracting passive tension at Ca2+ concentration 6.0 
solution from the total tension measured by the slack test. Tension at the different Ca2+ 
centration solutions was expressed as a fraction of the maximum tension (Ca2+ concentration 
4.5) obtained under identical conditions for that cell. Data were analysed by least-squares 
regression using the Hill equation as described by Hofmann et al. (Hofmann et al., 1991), 
Log [(Prel)/(1 – Prel)] = n(log [Ca2+] + k) 
 
Prel represents the tension expressed as a fraction of maximal tension, n is the Hill coefficient, 
and k is the intercept of the fitted line with the x-axis, which corresponds to the Ca2+ 
concentration at half-maximal tension (pCa50). Tension data were fitted with the following 
equation using Prism software through using constants derived from the Hill equation. 
Prel = [Ca2+]n/(kn + [Ca2+]n) 
 
2.5 Data Analysis 
2.5.1 Statistical Analysis 
All statistical analysis was conducted using GraphPad Prism 8 software. A student’s t-
test (unpaired t-test) was used to compare between diabetic and non-diabetic groups in 12-
week old tissue. A two-way Analysis of Variance (ANOVA) was used to compare between 
non-diabetic sedentary, diabetic sedentary, non-diabetic exercise and, diabetic exercise 
sample groups with Tukey’s post hoc test. Statistical significance was set at P < 0.05, and all 





3.1 Baseline Analysis of 12-week old nDM and DM Rats 
3.1.1 Verification of Total cTnI Expression 
A representative blot is presented in 3.1A, showing total cTnI protein bands at 28kDa. 
Total cTnI was expressed evenly in both diabetic (DM) and non-diabetic (nDM) groups 
(Figure 3.1A). Figure 3.1B shows a quantitative assessment of total cTnI in tissue from the 
left ventricle of non-diabetic and diabetic ZDF rats at 12 weeks of age. Total cTnI expression 
was unchanged in the left ventricle tissue from the diabetic rats compared to the non-diabetic 
rats (0.81 ± 0.094 vs. 0.82 ± 0.074, nDM vs. DM; Figure 3.1B). Thus, cTnI expression is the 




Figure 3.1. Total expression of cardiac troponin I in diabetic and non-diabetic rat hearts at 12 weeks of age. (A) 
Representative western blot image of cTnI and 𝛽-actin. (B) Individual value plots with a bar graph showing the 
quantification of cTnI in diabetic (DM) and non-diabetic (nDM) LV tissue of ZDF rats. 𝛽-actin was used as an internal 
control. n = 10 DM samples and 10 nDM samples. Values are represented as mean ± SEM. Statistics calculated with an 




3.1.2 Serine 23/24 Phosphorylation 
Figure 3.2A illustrates the level of cTnI phosphorylation at Ser23/24, measured in left 
ventricle tissue from non-diabetic and diabetic ZDF rats. A quantitative assessment shows 
that there is a significant increase in the levels of cTnI phosphorylation at Ser23/24 in diabetic 
cardiomyocytes compared to non-diabetic cardiomyocytes at 12 weeks of age (0.46 ± 0.11 vs. 
1.1 ± 0.22, nDM vs. DM, P < 0.05; Figure 3.2B). These data support my hypothesis that 
diabetes leads to an increase in phosphorylation at Ser23/24, potentially affecting the 
functionality of the myofilament protein, cTnI. 
 
 
Figure 3.2. Diabetes increases phosphorylation of cTnI at serine 23/24. (A) Representative western blot images of Ser23/24 
phosphorylated and cTnI as a control in DM and nDM left ventricle tissue in 12-week old ZDF rats. (B) Quantitative bar 
graph showing the levels of phosphorylation at Ser23/24 in diabetic (DM) and non-diabetic (nDM) ZDF rats LV tissue at 12 
weeks of age. n = 10 DM samples and 10 nDM samples. Values are represented as mean ± SEM. Statistics calculated with 
an unpaired, two-tailed, students t-test. All these experiments were performed as duplicates. *P < 0.05 vs. non-diabetic. 
 
3.1.3 Serine 150 Phosphorylation 
Figure 3.3A illustrates the level of cTnI phosphorylation at serine 150, measured in 
left ventricle tissue from non-diabetic and diabetic ZDF rats. A quantitative assessment shows 
that diabetic rats had significantly reduced levels of cTnI phosphorylation at Ser150 than that 
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of non-diabetic rats (3.2 ± 0.87 vs. 0.59 ± 0.15, nDM vs. DM, P < 0.05; Figure 3.3B). These 
results provide evidence to support my hypothesis that diabetes does result in altered levels of 
phosphorylation at Ser150.  
 
 
Figure 3.3. Diabetes decreases phosphorylation of cTnI at serine 150. (A) Representative western blot images of Ser150 
phosphorylated and cTnI as a control in diabetic and non-diabetic left ventricle tissue in 12-week old ZDF rats. (B) 
Quantitative bar graph showing the levels of phosphorylation at Ser23/24 in diabetic (DM) and non-diabetic (nDM) ZDF 
rats LV tissue at 12 weeks of age. n = 5 DM samples and 5 nDM samples. Values are represented as mean ± SEM. Statistics 
calculated with an unpaired, two-tailed, students t-test. All these experiments were performed as duplicates. *P < 0.05 vs. 
non-diabetic. 
 
3.1.4 Threonine 143 Phosphorylation 
Figure 3.4A illustrates the levels of cTnI phosphorylation at Thr143, measured in left 
ventricle tissue from non-diabetic and diabetic ZDF rats. A quantitative assessment shows no 
significant differences in the amounts of phosphorylation between non-diabetic and diabetic 
cardiomyocytes at Thr143 (0.39 ± 0.070 vs. 0.45 ± 0.094, nDM vs. DM, P = 0.61; Figure 
3.4B). Therefore, there is not enough evidence to accept my hypothesis that diabetes alters the 





Figure 3.4. Diabetes increases phosphorylation of cTnI at threonine 143. (A) Representative western blot images of Thr143 
phosphorylated and cTnI as a control in diabetic and non-diabetic left ventricle tissue in 12-week old ZDF rats. (B) 
Quantitative bar graph showing the levels of phosphorylation at Thr143 in diabetic (DM) and non-diabetic (nDM) ZDF rats 
LV tissue at 12 weeks of age. n = 5 DM samples and 5 nDM samples. Values are represented as mean ± SEM. All these 
experiments were performed as duplicates. 
 
3.2 Calcium Sensitivity Measurements 
3.2.1 Skinned Cardiomyocyte Calcium Sensitivity 
The pCa50, or Ca2+ concentration at which half-maximal tension is produced, is a 
measure of the Ca2+ sensitivity of cardiomyocytes. Figure 3.5 is an example of a tension-pCa 
curve for a single isolated cardiomyocyte. Due to lockdown, my project was modified to 
remove the training time for the Ca2+ sensitivity experiments. Instead, I assisted PhD 
candidate Angela Greenman in performing these experiments and analysed a subset of the 
data (discussed in this thesis). The example curve in Figure 3.5 shows data from a control 
non-diabetic sedentary, isolated cardiomyocyte. The results are fitted to a continuous 
sigmoidal curve, and the equation that fits the curve indicates the pCa50 of that particular 
cardiomyocyte. The results of each experiment with the fitted tension–pCa curve can be used 
to calculate the distribution of pCa50 within the non-diabetic sedentary (nDM SED), non-
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Figure 3.5. Representative tension-pCa curve. Myofilament pCa-tension relationship for an individual 
sedentary nDM left ventricular cardiomyocyte (n = 1).  The curve is drawn according to the parameters 
developed by fitting the data to the Hill equation. pCa50 = 5.425. Mean pCa50 for 20-week ZDF nDM sedentary, 
DM sedentary, nDM trained, and DM trained skinned cardiomyocytes can be analysed and used to find shifts 
indicating changes in Ca2+ sensitivity within tissue sample groups. 
 
3.2.2 Calcium Sensitivity in Response to Exercise Training 
Figure 3.6 shows the mean pCa-tension curves created for diabetic trained and non-
diabetic trained samples. The results indicate that the differences in pCa50 between the two 
sample groups are not significantly different. My data show a trend towards increased pCa50 
in diabetic trained cardiomyocytes compared to non-diabetic trained cardiomyocytes (5.428 
vs. 5.471, nDM EX vs. DM EX; Figure 3.6), indicated by a leftward shift. However, this data 
is not statistically significant, and hence no firm conclusions of altered calcium sensitivity can 
be supported. Again, this analysis was performed for only a subset of the animals within the 
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study, and when the full set of data is analysed by Ms Angela Greenman, we may see shifts in 
Ca2+ sensitivity indicating exercise mitigates the dysregulations in Ca2+ sensitivity observed 
in diabetic hearts. 
 
 
Figure 3.6. Calcium sensitivity is shifted in diabetic trained cardiomyocytes. Myofilament pCa50 increased in individual 
skinned diabetic trained rat heart cells, indicated by a leftward shift. Mean pCa-tension relationship (where pCa = -
log10[Ca2+]) obtained from skinned cardiomyocytes from ZDF non-diabetic sedentary, diabetic sedentary, non-diabetic 
trained, and diabetic trained rats’ hearts at 20 weeks of age. The pCa-tension curve is generated by normalising force at 
each pCa to maximal force measured in pCa 4.5. Statistics are calculated with a modified Hill equation. n = 3 diabetic 
trained, 3 diabetic sedentary, 3 non-diabetic trained, and 3 non-diabetic sedentary samples. 
 
3.3 Exercise Intervention Analysis of 20-week old nDM and DM Rats  
3.3.1 Verification of Total cTnI Expression 
A representative blot is presented in Figure 3.7A, showing total cTnI protein bands at 
28kDa, which corresponds to the expected size. As expected, the levels of total cTnI were 
expressed evenly in all non-diabetic sedentary, non-diabetic trained, diabetic sedentary and 
diabetic trained groups. Figure 3.6B shows a quantitative assessment of total cTnI expression 
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in tissue from left ventricle tissue from all four sample groups of ZDF rats at 20 weeks of age. 
Total cTnI expression was unchanged in the left ventricle tissue across all 4 groups (0.77 ± 
0.092 vs. 0.67 ± 0.036 vs. 0.69 ± 0.029 vs. 0.70 ± 0.040, nDM SED, DM SED, nDM EX, DM 
EX; Figure 3.7B). These results suggest that cTnI expression is the same in diabetic trained 
vs. diabetic sedentary vs. non-diabetic trained vs. non-diabetic sedentary ZDF rats’ hearts at 
20 weeks of age proceeding exercise training. 
 
 
Figure 3.7. Total expression of cTnI in diabetic sedentary and trained and, non-diabetic sedentary and trained rat hearts 
at 20 weeks of age. (A) Representative western blot image of cTnI and 𝛽-actin. (B) Individual value plots with a bar graph 
showing the quantification of cTnI in diabetic sedentary, diabetic trained, non-diabetic sedentary and, non-diabetic trained 
LV tissue of ZDF rats. 𝛽-actin was used as an internal control. n = 6 diabetic trained, 6 diabetic sedentary, 6 non-diabetic 
trained, and 6 non-diabetic sedentary samples. Values are represented as mean ± SEM. Statistics calculated with two-way 
ANOVA with Tukey’s post hoc test. All these experiments were performed as duplicates. 
 
3.3.2 Serine 23/24 Phosphorylation 
Expression of cTnI phosphorylation at Ser23/24 was measured in left ventricle tissue 
from non-diabetic sedentary, non-diabetic trained, diabetic sedentary and diabetic trained 
ZDF rats (Figure 3.8A). Diabetic trained rats show a significant reduction in the amount of 
phosphorylation at the Ser23/24 site, compared to non-diabetic trained rats (0.80 ± 0.070 vs. 
0.39 ± 0.024, nDM ex vs. DM ex, P<0.05; Figure 3.8B). Similarly, diabetic trained rats show 
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a significant reduction of the amount of phosphorylation at Ser23/24 compared to diabetic 
sedentary rats (0.68 ± 0.058 vs. 0.39 ± 0.024, DM SED vs. DM EX, P<0.05; Figure 3.8B). 
These results support my hypothesis that exercise can lead to altered levels of 
phosphorylation at Ser23/24 in the diabetic heart.  
 
 
Figure 3.8. Alterations in levels of phosphorylation at Serine 23/24 in the later stages of diabetes. (A) Representative 
western blot images of Ser23/24 phosphorylated and cTnI as a control in diabetic trained, diabetic sedentary, non-diabetic 
trained, and non-diabetic sedentary. (B) Quantitative bar graph showing the levels of phosphorylation at Ser23/24 in 
diabetic sedentary, diabetic trained, non-diabetic sedentary, and non-diabetic trained ZDF rats LV tissue at 20 weeks of age. 
n = 6 diabetic trained, 6 diabetic sedentary, 6 non-diabetic trained, and 6 non-diabetic sedentary samples. Values are 
represented as mean ± SEM. All these experiments were performed as duplicates. Statistics calculated with two-way ANOVA 
with Tukey’s post hoc test. *P < 0.05 vs. diabetic sedentary. ** < 0.01 vs. non-diabetic trained. 
 
3.3.3 Serine 150 Phosphorylation 
Expression of phosphorylation of cTnI at Ser150 was measured in left ventricle tissue 
from non-diabetic sedentary, non-diabetic trained, diabetic sedentary and diabetic trained 
ZDF rats (Figure 3.9A). No statistical significance was evident between any of the four 
sample groups. Diabetic trained rats show an increasing trend in the levels of phosphorylation 
compared to non-diabetic trained rats (0.33 ± 0.083 vs. 0.58 ± 0.075, nDM ex vs. DM ex, P = 
0.14; Figure 3.9B). In addition, diabetic trained rats also show increasing trends in the levels 
of phosphorylation diabetic sedentary rats (0.32 ± 0.092 vs. 0.58 ± 0.075, DM sed vs. DM ex, 
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P = 0.18; Figure 3.9B). Overall, these results do not provide enough evidence to support my 




Figure 3.9. Alterations in levels of phosphorylation at Serine 150 in the later stages of diabetes. (A) Representative western 
blot images of Ser150 phosphorylated and cTnI as a control in diabetic trained, diabetic sedentary, non-diabetic trained, and 
non-diabetic sedentary. (B) Quantitative bar graph showing the levels of phosphorylation at Ser150 in diabetic trained, 
diabetic sedentary, non-diabetic trained, and non-diabetic sedentary ZDF rats LV tissue at 20 weeks of age. n = 6 diabetic 
trained, 6 diabetic sedentary, 6 non-diabetic trained, and 6 non-diabetic sedentary samples. Values are represented as mean 
± SEM. Statistics calculated with two-way ANOVA with Tukey’s multiple post hoc test. All these experiments were performed 
as duplicates. 
 
3.3.4 Threonine 143 Phosphorylation 
Expression of cTnI phosphorylation at Thr143 was measured in left ventricle tissue 
from non-diabetic sedentary, non-diabetic trained, diabetic sedentary and diabetic trained, 
ZDF rats (Figure 3.10A). Diabetic trained rats show a significant reduction in the amount of 
phosphorylation at the Thr143 site, compared to non-diabetic trained rats (1.0 ± 0.096 vs. 0.48 
± 0.070, nDM ex vs. DM ex, P<0.01; Figure 3.10B). Similarly, diabetic trained rats had a 
significant reduction of the amount of phosphorylation at Thr143, compared to diabetic 
sedentary rats (1.1 ± 0.12 vs. 0.48 ± 0.070, DM sed vs. DM ex, P<0.01; Figure 3.10B). 
Diabetic trained, rats also show a significant reduction in the amount of phosphorylation 
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when compared to the non-diabetic sedentary rats (1.1 ± 0.10 vs. 0.48 ± 0.070, nDM sed vs. 
DM ex, P<0.01; Figure 3.10B). These results provide enough evidence to support my 




Figure 3.10. Alterations in levels of phosphorylation at Threonine 143 in the later stages of diabetes. (A) Representative 
western blot images of Thr143 phosphorylated and cTnI as a control in diabetic trained, diabetic sedentary, non-diabetic 
trained, and non-diabetic sedentary. (B) Quantitative bar graph showing the levels of cTnI phosphorylation at Thr143 in 
diabetic trained, diabetic sedentary, non-diabetic trained, and non-diabetic sedentary ZDF rats LV tissue at 20 weeks of age. 
n = 6 diabetic trained, 6 diabetic sedentary, 6 non-diabetic trained, and 6 non-diabetic sedentary samples. Values are 
represented as mean ± SEM. Statistics calculated with two-way ANOVA with Tukey’s post hoc test. All these experiments 







This project aimed to investigate the role that cTnI plays in the diabetic heart and 
examine whether phosphorylation at cTnI serine and threonine residue sites was altered in 
non-diabetic and diabetic ZDF rats. Furthermore, I investigated whether pCa50 is reduced in 
the diabetic heart initially or after eight weeks of uncontrolled hyperglycemia. Additionally, I 
aimed to determine whether exercise can alter phosphorylation activity and pCa50 responsible 
for cellular functional changes in the myocardium in the late stages of diabetes.  
 
I hypothesised that in ZDF diabetic tissue at both 12 and 20 weeks of age, the results 
would show alterations in cTnI phosphorylation activity that would correspond to a reduction 
in pCa50. I also hypothesised that in 20-week old ZDF rat diabetic left ventricle tissue; 
exercise training would cause alterations in cTnI phosphorylation activity that would 
correspond to an increase in pCa50. 
 
My results indicate that cTnI protein phosphorylation was altered in diabetic 
myocardium, suggesting a reduction in Ca2+ sensitivity at 12 weeks of age. Additionally, cTnI 
protein phosphorylation was altered significantly in trained diabetic myocardium compared to 
sedentary diabetic myocardium, suggesting an increase in Ca2+ sensitivity. 
 
4.1 Total Cardiac Troponin I Expression Measurements 
The phosphorylation of cTnI represents an important physiological mechanism for 
altered myofilament properties and contributes to contractile dysfunction observed in diabetic 
patients (Jweied et al., 2005; Layland et al., 2005). An initial objective of this study was to 
identify the total expression of cTnI and get an indication of whether it was increased, 
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decreased or not changed at all in diabetic cardiomyocytes compared to non-diabetic 
cardiomyocytes. This analysis was conducted in left ventricle tissue at 12 weeks of age as this 
is a well-established age to develop hyperinsulinemia and is thought to be modelling early-
onset of diabetic heart dysfunction (Reed & Scribner, 1999). As expected, the protein 
expression of cTnI was similar between the two groups, indicating that cTnI protein 
expression may not change in diabetic myofilaments and non-diabetic myofilaments prior to 
administration of exercise. This again suggests that cTnI expression that is distinct from 
diabetes is not influencing the differences in levels of phosphorylation that is observed 
between the two sample groups. 
 
4.2 Cardiac Troponin I Phosphorylation Measurements at 12 Weeks 
of Age 
The type 2 diabetic heart experiences the development of cardiovascular diseases, 
commonly displaying symptoms of impaired diastolic performance (Baldi et al., 2006). It is 
believed this is due to intrinsic myofilament properties being altered, affecting the cellular 
structure and function of cardiomyocytes (Layland et al., 2005). The findings from this 
current study are consistent with this theory. We tested three phosphorylation sites, Ser23/24, 
Ser150, and Thr143, within cTnI known to modulate Ca2+ sensitivity (Pfitzer et al., 1982; 
Noland et al., 1989; Ouyang et al., 2010; Solaro, 2011). Ser23/24 results show a significant 
increase in the levels of phosphorylation in diabetic rat hearts compared to non-diabetic rat 
hearts, indicating a functional change in the myofilament. However, the difference in the 
levels of phosphorylation at Thr143 were not significantly different, potentially due to 
variability among the animals in the protocol. In contrast, phosphorylation was significantly 
increased in diabetic rats’ hearts at Ser150 compared to non-diabetic hearts. In line with my 
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hypothesis, diabetic cardiac tissue shows alterations in cTnI phosphorylation that might 
underpin the cellular changes in myofilament properties. 
 
4.2.1 Modifications at Ser23/24 
In Figure 3.2, diabetic ZDF tissue shows a significant increase in the amount of 
phosphorylation at Ser23/24 compared to non-diabetic ZDF tissue. Based on prior studies, 
this result suggests a reduction in Ca2+ sensitivity that may be linked to the upregulation of 
PKA activity (Figure 4.1). When considering PKA phosphorylation of cTnI, literature 
classifies the reduction in myofilament Ca2+ sensitivity as a result of the phosphorylation at 
serine residues in positions 23 and 24 of the N-terminal (Solaro & Rarick, 1998; Noguchi et 
al., 2004; Solaro, 2011). Myofilament Ca2+ desensitisation and the rate of Ca2+ dissociating 
from TnC is characteristic of PKA-dependent phosphorylation, which is mediated by β-
adrenergic stimulation (Layland et al., 2005), resulting in acceleration of relaxation (Hoh et 
al., 1988). Nonetheless, multiple studies take contrary positions showing 𝛽-adrenergic 
stimulation results in no change in the rate of cross-bridge cycling or shortening velocity, in 
addition to Ca2+ sensitivity (Hofmann & Lange 3rd, 1994; Janssen & De Tombe, 1997; Johns 
et al., 1997). Although we do not directly measure PKA or β-AR expression, this data would 
support others’ conclusions that β-AR signalling is impaired or desensitised in the diabetic 
heart (Thaung et al., 2015).  
 
Another possible explanation based on the current literature is that the observed 
alterations in phosphorylation are a consequence of PKG-dependent phosphorylation. 
Evidence generated supports the concept that PKG is also contributing to the phosphorylation 
of cTnI at Ser23/24 with comparable properties to those of PKA (figure 4.1), albeit, at slower 
rates than PKA (Blumenthal et al., 1978). Crucially, PKG I expression is identified in 
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cardiomyocytes (Wollert et al., 2003) and the treatment of skinned cardiac preparations with 
PKG reduced myofilament Ca2+ sensitivity (Pfitzer et al., 1982). Conversely, there is still 
limited evidence on the responses of PKG on cTnI phosphorylation and Ca2+ sensitivity in the 
myofilament. The difficulty in pinpointing the precise effects of PKG on cTnI 
phosphorylation is due to the uncertainty surrounding the impact of PKG on other proteins, 
including the reduction of L-type Ca2+ current or increased sarcoplasmic reticulum Ca2+ 
uptake (Shah, 1996). 
 
It is possible, therefore, that the results I observed are a consequence of PKA and PKG 
upregulation and that these results might support the idea that impaired β-AR responsiveness 
contributes to an increase in Ser23/24 phosphorylation. However, further research is required, 
as the modifications in diabetic myofilaments might be unrelated to Ser23/24 phosphorylation 
or the observed Ser23/24 phosphorylation events may be connected to various other cardiac 
kinases. 
 
4.2.2 Modifications at Thr143 
In Figure 3.4, diabetic ZDF tissue did not show amounts of phosphorylation that were 
significantly different from that observed in non-diabetic ZDF tissue. The functional effects 
of Thr143 phosphorylation in the myofilament are not as well understood. Prior studies have 
noted that cTnI can be phosphorylated by PKC at Thr143, resulting in desensitisation of the 
myofilaments (Wang et al., 2006) (Figure 4.1). This could be due to the strong relationship 
between diabetes and PKC reported in the literature (Jweied et al., 2005). PKC activation has 
shown both negative (Takeishi et al., 1998; Montgomery et al., 2002) and positive inotropic 
effects (Pi et al., 2002), as well as negative (Takeishi et al., 1998) and positive lusitropic 
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effects (Westfall & Borton, 2003), suggesting numerous myofilament-based and non-
myofilament effects of PKC. 
 
Another possible explanation for this, is the functional consequence of phosphorylated 
Thr143 might be dependent on communicating with Ser43/45 (Lang et al., 2017), as the 
literature suggests functional effects associated with both amino acid residue sites are 
attenuated or strengthen depending on the secondary phosphorylation. It has been 
demonstrated that secondary phosphorylation at PKC sites Thr143 and Ser43/45 could help to 
maintain homeostatic contractile function during chronic cTnI phosphorylation as observed in 
diabetic hearts. Lang et al. (2017) found Thr143 phosphorylation heightened the effects of 
Ser43/45 phosphorylation, resulting in a reduction in Ca2+ sensitivity. It can thus be suggested 
that multiple phosphorylation sites may interact together and change cellular functions.  
 
4.2.3 Modifications at Ser150 
In Figure 3.3, the results show that diabetic ZDF tissue had decreased phosphorylation 
at Ser150 when compared to non-diabetic ZDF tissue. Prior literature indicates that a decrease 
in AMPK activity leads to a reduction in cTnI phosphorylation at Ser150 (Figure 4.1). AMPK 
is a serine/threonine-protein kinase, and evidence signifies that AMPK can phosphorylate 
cTnI (Hardie & Carling, 1997; Kobayashi & Solaro, 2005; Oliveira et al., 2007; Sancho Solis 
et al., 2011). Given this, the evidence established cTnI Ser150 phosphorylation as 
functionally significant, indicating that Ca2+ regulation was altered though cTnI pseudo-
phosphorylation, affecting the interaction between cTnI and cTnC (Ouyang et al., 2010). 
Ouyang et al.’s (2010) study focused on the selectivity of AMPK for cTnI phosphorylation 
sites and confirmed that Ser150 and Ser23 were targeted quite selectively as Ser22 and 
Thr143 were not observed to be phosphorylated. The current study results indicate that the 
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reduction in Ser150 phosphorylation could be due to a reduction in AMPK activity resulting 
in a decrease in Ca2+ sensitivity. Moreover, this current study was successful in identifying 
that diabetes might play a role in the dysregulation of Ser150 phosphorylation. 
 
Collectively, these findings from Figure 3.2, 3.3, and 3.4 could explain why alterations 
at specific cTnI phosphorylation residue sites affect cardiac myofilament properties, that may 
underlie the decreased contractile function of the ventricle often characterised in diabetic 
cardiomyopathy. This is based off similar findings indicating that diabetes can result in 
altered myocardium functionality resulting in weaker force generation, characteristic of 
contractile dysfunction (Diffee et al., 2001). These results provide evidence of alterations in 
cTnI phosphorylation in diabetic tissue. 
 
4.3 Single-cell Calcium Sensitivity Measurements  
There is limited research on the relationship between myofilament Ca2+ sensitivity and 
diabetic cardiomyocytes, but collectively they demonstrate that Ca2+ sensitivity is reduced in 
human diabetic cardiomyocytes (Jweied et al., 2005). Based on these findings, we 
hypothesised that cardiomyocytes from diabetic rat hearts would show decreased pCa50 values 
compared to non-diabetic counterparts. Interestingly, diabetic trained cardiomyocytes showed 
a trend towards increased pCa50 (though this was not significant), potentially indicating an 
increase in Ca2+ sensitivity compared to non-diabetic trained cardiomyocytes (Figure 3.6). If 
this difference became significant once the entire set of animals is analysed, it would stand in 
contrast to published findings and our hypothesis. This discrepancy could be attributed to a 
compensatory mechanism to maintain normal systolic function that could also have adverse 
effects on the diastolic function as the disease progresses. Interestingly, the data indicates an 
increase in pCa50 values in skinned cardiomyocytes from diabetic trained rats compared to 
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diabetic sedentary rats, indicating sensitised diabetic myofilament proteins, this would be 
evidenced by a leftward shift in the tension-pCa relationship. This means more tension is 
developed at submaximal Ca2+ concentration.  
 
These results corroborate findings which suggested that the reduction in Ca2+ sensitivity 
in these works provide an explanation as to why reductions in contractility or compensation to 
improve rates of relaxation is observed in the diabetic heart (Piccini et al., 2004). This result 
may be explained by the fact that exercise induces increases in isometric tension observed in 
myocardial preparations (Tibbits et al., 1981) and increases in cell shortening observed in 
single cardiomyocytes (Moore et al., 1993). Previous work examining the cellular basis 
underlying the increase in myocardial contractility induced by exercise has focused on 
training-induced alterations in mechanisms that may increase intracellular Ca2+ concentration 
during activity, however many have shown inconclusive results (Fitzsimons et al., 1990; 
Laughlin et al., 1991; Lankford et al., 1998). Although the present study is one of the first to 
directly measure Ca2+ sensitivity of tension in relation to exercise training in diabetic hearts, 
with a greater sample size, our data might suggest that Ca2+ sensitivity may be increased in 
trained diabetic cardiomyocytes. 
 
4.4 Cardiac Troponin I Phosphorylation Measurements at 20 Weeks 
of Age 
It is well-established that exercise as an intervention for CVD results in positive 
adaptations of cardiac function, thus improving the health of type 2 diabetic patients. Whilst 
the role of chronic exercise training in patients with a cardiovascular disease has been 
previously investigated (Diffee et al., 2001; Diffee & Nagle, 2003; Lear et al., 2017), its role 
in the myofilaments of a diabetic heart is relatively unknown. Data from this study may 
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provide a possible explanation as to why the pathological effects of diabetes can be improved 
by exercise. The data shows that the diabetic left ventricle tissue could improve the Ca2+ 
sensitivity of the myofilament following moderate-intensity exercise training, as they exhibit 
alterations in phosphorylation levels contrary to non-diabetic counterparts.  
 
4.4.1 Sedentary Response  
We tested the same three residue sites, investigated in 12-week old rats’ hearts, 
specific to cTnI, Ser23/24, Ser150, and Thr143, within cTnI known to modulate Ca2+ 
sensitivity (Pfitzer et al., 1982; Noland et al., 1989; Ouyang et al., 2010; Solaro, 2011). A 
note of caution is due here since the differences observed were not significant; therefore, a 
conclusion cannot be made, however, phosphorylation at Ser23/24 was trending towards an 
increase in the diabetic sedentary hearts compared to the non-diabetic hearts. This also 
accords with our earlier observations along with literature, which indicates that diabetes could 
be intervening in the pathways regulating phosphorylation activity by PKA and PKC at 
specific residue sites within cTnI. Consequently, this results in changes to protein structure 
and function, which might impair Ca2+ sensitivity. Phosphorylation at Ser150 was also 
trending towards a decrease in the diabetic sedentary heart tissue compared to non-diabetic 
hearts. This finding was also reported in my 12-week data suggesting a change in the levels of 
phosphorylation, possibly due to dysregulations in the AMPK pathway.  
 
4.4.2 Ser23/24 Phosphorylation in Response to Exercise 
The second aim of this study sought to determine if exercise could intervene in the 
amount of phosphorylation observed in diabetic rats’ heart and reverse the pathological 
effects that are observed in a diabetic heart. One of the most interesting findings was that 
observed in Figure 3.7 showing that phosphorylation at Ser23/24 in diabetic trained rats’ 
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hearts was decreased when compared to non-diabetic trained, and diabetic sedentary rats’ 
hearts. This implies that, upon moderate-intensity exercise training, the amount of 
phosphorylation is altered in the diabetic cardiomyocytes.  
 
Very little research has investigated the role of exercise as a mechanism for altering 
the amount of cTnI phosphorylation by which mechanical properties are regulated in the 
diabetic heart. Interestingly, the results showing a reduction in the amount of phosphorylation 
observed at Ser23/24 suggests an increase in Ca2+ sensitivity which may be explained by the 
relationship between PKA, β-AR protein expression and exercise (Haley et al., 2015). 
Research by Leosco et al. (2013) has illustrated that exercise reverses β-AR dysfunction 
through modulating G-protein-dependent adenylyl cyclase activation and restoring cardiac 
receptor levels and activity. This becomes important because several reports have stated that 
diabetes commonly results in β-AR dysfunction whereby PKA activation is increased (Jweied 
et al., 2005; Leosco et al., 2013; Haley et al., 2015). However, exercise might provide a way 
to improve β-AR signalling and responsiveness in type 2 diabetic hearts. Similar observations 
also have been reported in post-ischemic hypertrophied failing myocardium, demonstrating 
that exercise evokes similar effects on β-AR signalling and responsiveness, resulting in the 
enhanced cardiac inotropic state (Leosco et al., 2013). Furthermore, β-AR responses were 
improved in intact cardiomyocytes of diseased hearts illustrating that moderate-intensity 
exercise training might restore β-AR signalling alterations in the myocardium that contributes 
to left ventricle dysfunction. Therefore, exercise training could be a significant factor causing 




4.4.3 Thr143 Phosphorylation in Response to Exercise 
As previously mentioned, the functional effects of phospho-Thr143 are still relatively 
unknown, although it is believed to be a PKC target site, along with Ser23/24. Interestingly, 
Figure 3.9 shows that the amount of phosphorylation observed at Thr143 was significantly 
altered from diabetic trained rats hearts to diabetic sedentary hearts, indicating that exercise 
might be altering PKC-dependent phosphorylation in the diabetic heart. It is well-established 
that contractility is regulated by cTnI phosphorylation by PKC and that PKC is activated in 
diabetes (Kirk et al., 2009; Lang et al., 2015). However, the activation of PKC-dependent 
phosphorylation at Thr143 is associated with a reduction in Ca2+ responsiveness, in agreement 
with impaired contractility characteristic of the type 2 diabetic heart.  
 
In the case of the trained diabetic rats, exercise might be partially inhibiting the PKC 
pathway targeting Thr143, returning the pathway to a homeostatic activity level. Another 
alternative explanation is that exercise is heightening the cross-talk between Thr143 and 
Ser43/45, as previously mentioned in section 4.2.2. Collectively, these might be contributing 
to reduced phosphorylation, allowing the myofilaments to increase their Ca2+ responsiveness, 
inducing the heart to function at near-maximum kinetics. Previous work using reconstituted 
skinned fibre bundles in which endogenous cTnI was mutated to mimic constitutive 
phosphorylation showed that phosphorylation at Thr144 caused a reduction in Ca2+ sensitivity 
and filament sliding velocity (Burkart et al., 2003). However, PKC activation is known to 
occur through several other pathways also associated with diabetes (Jweied et al., 2005). Prior 
studies have noted that serum levels and hyperglycemia, commonly observed in diabetic 
patients, may contribute to the upregulation, eliciting effects that also impair the cardiac tissue 
(Shiba et al., 1993; Karar et al., 2015). Overall, it is encouraging that the results from trained 
diabetic rats’ hearts show reductions in amounts of phosphorylation, which suggest an 
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increase in Ca2+ sensitivity, and this could ultimately lead to an improvement in cardiac 
contractility of the diabetic heart. To develop a full picture of cTnI phosphorylation at Thr143 
and the implications exercise is causing, might require further research, in particular, to fully 
understand the importance of potential cross-talking between Ser43/45 and Thr143. 
 
4.4.4 Ser150 Phosphorylation in Response to Exercise 
One unanticipated finding was that moderate-intensity exercise had little effect on the 
levels of phosphorylation at phospho-Ser150. Figure 3.8 illustrates alterations in the levels of 
phosphorylation at Ser150 between the diabetic trained cardiomyocytes, diabetic sedentary, 
and non-diabetic trained cardiomyocytes; however, these differences are only indicating 
potential trends. The trained diabetic samples demonstrate a reducing trend in the levels of 
phosphorylation, which suggest an increase in Ca2+ sensitivity. Literature has indicated that 
the phosphorylation at Ser150 might be associated with the interaction of cTnI with cTnC 
affecting thin filament Ca2+ modulation, but also the possibility of cross-talking with PKA-
dependent Ser23/24 phosphorylation (Nixon et al., 2012). The role of AMPK to modulate 
energy substrate availability as a regulator of heart function has been established (Nixon et 
al., 2012); however, the literature also suggests that AMPK is directly coupled to a 
mechanical effect of contraction at the myofilament level following Ser150 phosphorylation 
(Arad et al., 2007). Although our results were not significantly different, they show trends 
that encourage this idea. Exercise training stimulated an increasing trend in the levels of 
phosphorylation, in line with literature which states that alterations in the AMP/ATP ratio can 
result in AMPK phosphorylation. This often occurs in a diseased heart due to the increased 
stress on the heart, increasing Ser150 phosphorylation (Sancho Solis et al., 2011). Exercise 
might provide a mechanism to balance the AMP/ATP ratio as such coupling of AMPK 
increasing energy substrate availability to a cTnI Ser150-enhanced myofilament response to 
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Ca2+, might be beneficial to maintaining enhanced contractility during times of stress without 
the enhanced energetic cost of increased Ca2+ cycling.  
 
The effects of AMPK-dependent phosphorylation at Ser150 might also contribute to 
blunt cTnI PKA-dependent phosphorylation, which literature suggests results in an increase in 
Ca2+ sensitivity (Hoh et al., 1988). This current study indicates that exercise alters 
phosphorylation at Ser23/24, suggesting an increase in Ca2+ sensitivity which, as previously 
discussed, could be due to a return to full functionality of β-AR stimulation. However, this 
could also be due to cross-talking within cTnI to blunt myofilament PKA-dependent 
functional effects, resulting in uncoupling of the myofilament to the β-AR response. 
Nevertheless, whether cTnI phosphorylation at the AMPK site is indeed elevated in the 
diabetic trained heart cannot be established, since we did not have sufficient results to make 
this conclusion.  
 
Although the mechanisms that underlie cardiac myofilament dysfunction in 
association with diabetes and the amount of phosphorylation occurring cannot be determined 
from this study, it is possible that altered myofilament contractile protein phosphorylation by 
PKA, PKC, PKG, and AMPK at Ser23/24, Ser150 and Thr143, plays a significant role in this 
process.  
 
Regardless of the mechanism, levels of cTnI phosphorylation and changes observed in 
the diabetic rats’ hearts might be affected by moderate-intensity exercise, altering the Ca2+ 
sensitivity of the myofilaments through changes in levels of phosphorylation, thus, affecting 
the global function of the heart. An increase in Ca2+ sensitivity would provide one explanation 
for the improvement in contractility due to less Ca2+ required to generate a normal amount of 
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force in the diabetic cardiomyocyte. Moreover, it could be an explanation for diastolic 
dysfunction and arrhythmias commonly observed in diabetic patients. Viewed another way, 
the relatively preserved global systolic function observed in diabetic patients, in general, 
could be due to a reduction in Ca2+ sensitivity compensated for by a potential maladaptive 
increase in Ca2+ to generate a force similar to a non-diabetic cardiomyocyte.  
 
 
This study provides the first comprehensive assessment of the effects of exercise on 
myofilament protein, cTnI, phosphorylation in a diabetic rats’ heart. The findings from the 
present study, while preliminary, suggest that a moderate-intensity exercise scheme may 
modulate myofilament proteins and reverse phosphorylation activity that may correspond to 
an increase in Ca2+ sensitivity. However, further investigation is required to expand our 
Figure 4.1. Schematic diagram showing the major cTnI phosphorylation pathways involved in the regulation of 
cardiac function. The specific sites being phosphorylated in combination with the activity of protein phosphatases 
regulates the changes in contractility of cTnI phosphorylation. Phosphorylation is represented by P and the kinases 
phosphorylating the residue sites are located left of the arrow. The changes in myofilament properties that result in 
alterations of heart function are indicated on the right. Amino acid and carboxy termini of cTnI are indicated by NH2 and 
COOH, respectively. (Gold, 2020, Original figure). 
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knowledge of the troponin complex, and the possibility that exercise is causing alterations in 
phosphorylation activity that enhance cardiac structure and function in a diseased heart. 
 
4.5 Limitations 
Several limitations must be taken into account with the findings from this honours 
project. Firstly, there was concern surrounding the stability of the post-translational 
modifications in the 12-week old tissue, as they are known to be less stable over time. 
Literature suggests that, in cTnI, by the seventh day of storage, there is a significant reduction 
in phosphorylation taking into consideration anaesthetic regimen and sample storage 
conditions (Utter et al., 2015). Additionally, there was an overall decrease in myofilament 
phosphorylation from samples stored from 30 to 90 days. This study attempted to complete 
experiments as quickly as possible; however, it is possible that we were unable to measure 
phosphorylation in its physiological state. Precautions, such as storage on ice and protease 
inhibitors, were used to prevent changes in post-translational modifications during 
experimentation. 
 
Secondly, the length of the exercise protocol was also subject to technical difficulties. 
Previous studies have used an intervention period of 10-weeks; however, our intervention 
period was only 8-weeks long, not including the familiarity period which made our protocol 
two weeks shorter than other protocols (using healthy rats). An 8-week period was chosen due 
to a significant decline in quality of life for the ZDF rats, which develop cataracts and malaise 
around 20 weeks of age (Katsuda et al., 2014). We decided it was unethical to train the rat 
past this point. Another factor limiting the ability to extend the running protocol is that ZDF 





4.6 Clinical Implications 
The current data highlights the important role performed by cTnI phosphorylation at 
Ser23/24, Ser150, and by Thr144 in the alteration of myofilament function in the diabetic 
heart. The profound effects of cTnI phosphorylation are determined by the combination of 
kinases and phosphatases activated and the specific sites phosphorylated. Primarily, the Ca2+ 
sensitivity of the myofilament may be dramatically affected by differential phosphorylation at 
numerous positions within cTnI. Phosphorylation of cTnI at Ser23/24 reduces Ca2+ 
sensitivity, while phosphorylation at Thr143 reduces contractile force; effectively impairing 
the function of the heart cell. In contrast, phosphorylation at Ser150 increases Ca2+ sensitivity 
and contractility, improving function. Under physiological conditions, these effects on 
contractile function impact the fine-tuning in cardiac function performance, thus optimising 
cardiac performance under conditions of different states. These findings may help us to 
understand what is occurring under pathological conditions of diabetes and how it results in 
disruptions to cellular homeostasis, which could result in impaired contractile function 
commonly observed in diabetic patients. 
 
The present study also raises the possibility that exercise, at least in part, is modulating 
the mechanisms responsible for altering the amount of phosphorylation of various amino acid 
residues within cTnI, a process by which mechanical properties are changing in the diabetic 
heart. The principal theoretical implication of this study is that the alterations occurring to the 
levels of phosphorylation suggest an increase in Ca2+ sensitivity which, functionally, would 
result in improvements in cardiac contractility and could ultimately lead to an improvement in 
the patient’s quality of life. With further research, a drug could be developed that targets the 
same mechanism that exercise is targeting. Studies to develop a clinically suitable drug that 
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mimics the same effects as the exercise protocol should be considered to minimise the 
substantial impact that heart disease has on patients suffering from type 2 diabetes.  
 
4.7 Future Directions 
In this thesis, despite these promising results, questions remain. Further research 
should be undertaken to investigate whether high-intensity exercise training can elicit greater 
cardiac adaptations than moderate-intensity exercise, as this current training protocol was 
modelled on a low-intensity running intervention previously used in ZDF rats (VanHoose et 
al., 2010). The speed and duration of the running were increased from the previous study to 
better match rat-running protocols shown to effectively increase aerobic capacity after ~10 
weeks of training which closely model a moderate-intensity training protocol (Diffee et al., 
2001; Wisloff et al., 2007). However, it would be of interest to investigate high-intensity 
exercise as the literature indicates that vigorous exercise in cardiac patients is a safe 
intervention that improved VO2max, cardiac output, and left ventricular stroke volume 
(Ekblom et al., 1968). Similarly, data quantifying the safety of high-intensity interval training 
in diabetic patients is limited, with only one study dealing with the risk of moderate versus 
high-intensity exercise in cardiac patients (Rognmo et al., 2012). Interestingly, their results 
suggest that cardiac complications were 1 per 129,466 moderate-intensity training hours 
versus 1 per 23,182 high-intensity training hours. More recently, studies have shown that 
high-intensity interval training, integrating short burst of high-intensity exercise separated by 
moderate-intensity intervals, heightened left ventricular contractility and reversed remodelling 
of the left ventricle (Wisloff et al., 2007).  
 
Another area that could benefit from further research is the pCa50 of isolated diabetic 
cardiomyocytes in response to training, as the project under discussion obtained limited data 
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on the Ca2+ response to exercise training in diabetic rats’ hearts. Future studies may wish to 
examine whether the trends observed in the ZDF trained rats’ isolated cardiomyocytes are 
observed in human trained diabetic cardiomyocytes. Recent unpublished research from our 
group has indicated that in human diabetic cardiomyocytes, there is a decrease in pCa50 when 
compared to non-diabetic cardiomyocytes. This reduction in pCa50 could be due to changes in 
myofilament structure and functions, in particular cTnI. Although their study did not test the 
effect of exercise, it is believed that exercise can reverse this pathological mechanism of 
diabetes to increase the Ca2+ sensitivity (Moore et al., 1993); however, research has not fully 
identified the pCa50 in trained diabetic cardiomyocytes. Future projects may test both human 
and rat heart tissue, following a high-intensity exercise protocol. As we cannot pre-determine 
human type 2 diabetic patients, this observation could be done following a training protocol 
for some time after their diagnosis.  
 
Further studies could be continued using the animal model of type 2 diabetes - the ZDF 
rat. With evidence from the present study in addition to work done by Diffee et al. (2001), 
associating alterations in cTnI phosphorylation through exercise training with an increase in 
Ca2+ sensitivity, the effects this has on the contractile mechanisms in the diabetic heart 
following a training protocol remains to be elucidated. An increase in pCa50 would result in a 
greater level of isometric tension generation at the same intracellular Ca2+ concentration; this 
has been widely reported with effects of training on isomeric tension generation in the 
myocardium (Diffee et al., 2001). It has been suggested that a training-induced increase in 
Ca2+ sensitivity of the myofilaments would be consistent with literature demonstrating that in 
trained cardiomyocytes, the contractile response is more sensitive to intracellular and 
extracellular Ca2+. Therefore, future studies may wish to examine whether exercise training 
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would lead to an increase in Ca2+ sensitivity resulting in an increase in contractile force in the 
myocardium through echocardiography and Langendorff apparatus.  
 
To develop a full picture, another research question that could be asked includes 
investigating the kinases responsible for the phosphorylation at the various amino acid 
residues within cTnI. The decrease in pCa50 in diabetic hearts is associated with high levels of 
cTnI phosphorylation, including the PKA and PKG sites Ser23/24 (Messer et al., 2007), 
moreover, increased PKC activity at Thr144 and Ser43/45 is also reportedly increasing pCa50 
in diabetic hearts (Layland et al., 2005). Equally important, decreased AMPK activity might 
be causing a decrease in phosphorylation at Ser150. Such an effect could be studied in left 
ventricle tissue of a ZDF rat via enzyme activity assays for protein kinases – PKA, PKC, 
PKG, and AMPK. 
 
4.8 Conclusion 
The purpose of this honours project was to determine the role of cTnI in diabetic hearts 
and investigate whether exercise intervened in this mechanism. These findings suggest that 
altered phosphorylation of cTnI residues led to changes in cellular function in the diabetic 
heart and, further, that these alterations could be mitigated via exercise training. With the data 
gathered in this project, I was able to accept my hypotheses. The experiments show a 
potential mechanism to reverse the pathological effects of type 2 diabetes in the 
cardiovascular system, lending support to the notion that, currently, exercise is the best 
therapeutic option for type 2 diabetic patients. I have outlined various future directions of 
research, which may aid in understanding the impact of diabetes with the interaction of 
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